BridgeBio Pharma, Inc. (BBIO) stock plummeted 5.06% in the intraday trading on Monday, as the biopharmaceutical company disclosed mixed trial results for its investigational therapies.
The company announced the publication of 18-month results from PROPEL 2, a Phase 2 trial of its investigational therapy infigratinib in children with achondroplasia, a form of dwarfism. While the therapy showed some positive effects, the results were not as promising as investors had hoped, leading to disappointment in the market.
Additionally, BridgeBio presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM (transthyretin amyloid cardiomyopathy) at the American Heart Association Scientific Sessions. The data, while encouraging, failed to significantly boost investor confidence in the therapy's potential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.